title: Experimental change on dopaminergic neurons in striatum of Parkinson disease rats.
abstract: Parkinson's disease (PD) is a common neurodegenerative disorder characterized by selective and progressive demise of dopamine-containing neurons in the midbrain. In this study, we observe the expression of c-Jun in the striatum of rats with 6-hydroxydopamine (6-OHDA)-lesions after apomorphine (APO) intraperitoneal injection (ip) in substantia nigra compacta (SNc), and to study the mechanism of the rotations behavior.
  
  
  
  The 6-OHDA was unilaterally injected into rat right SNC. The APO- induced abnormal rotations were investigated on the 1st, 4th, 7th, 14th, 21st days after lesion, respectively. Meanwhile dopaminergic degeneration and c-Jun expression were observed with microscope. Nissl's body staining and immunohistochemical method (ABC) were employed to study the changes of tyrosine hydroxylase (TH) and c-Jun in DA neurons.
  
  
  
  We found that the number of dopaminergic neurons decreased gradually in the lesioned site and those neurons' electron-microscopic structure was severe damaged. There were over 75% of dopaminergic neurons lost, contralateral rotations over 7 turns per minute and c-Jun expressing in the ipsilateral striatum.
  
  
  
  Dopaminergic neurons deletion may be linked to upregulation of c-Jun.
authors.affiliation: School of Pharmacy, Anhui Medical University, Hefei, China. chenxiaoyuzlx@yahoo.com.cn
authors.forename: X Y
authors.initials: XY
authors.lastname: Chen
authors.forename: J
authors.initials: J
authors.lastname: Li
authors.forename: W Q
authors.initials: WQ
authors.lastname: Qi
authors.forename: S H
authors.initials: SH
authors.lastname: Shen
mesh_terms: D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D018491:Dopamine Agonists / Q000494:pharmacology; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009474:Neurons / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D016627:Oxidopamine / Q000494:pharmacology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D016755:Proto-Oncogene Proteins c-jun / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D019956:Stereotypic Movement Disorder / Q000139:chemically induced / Q000473:pathology; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism; D015854:Up-Regulation
chemical_list: D018491:Dopamine Agonists; D016755:Proto-Oncogene Proteins c-jun; D016627:Oxidopamine; D001058:Apomorphine; D004298:Dopamine